CancerNetwork® spoke with Dr. William Wood on the clinical risk of chemotherapy in early breast cancer.
Dr. Rebecca Dent, oncologist at the National Cancer Center, Singapore, discusses the rationale for immunotherapy in early-stage breast cancer.
Dr. Leisha Emens of the University of Pittsburgh Medical Center's Hillman Cancer Center discusses the overall survival in the KATE2 study.
Cancer Network spoke with Dr. Jennifer A. Ligibel on the diet and exercise interventions to reduce breast cancer recurrences.
Cancer Network spoke with Kelly Hunt, MD, professor and chair of the department of breast surgical oncology at the MD Anderson Cancer Center in Houston, about the role of surgery in metastatic breast cancer.
Cancer Network spoke with Fergus Couch, PhD, professor and researcher at the Mayo Clinic in Rochester, Minnesota, about new genes implicated in triple-negative breast cancer risk.
Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ.
Cancer Network spoke with Ruth Oratz, MD, a medical oncologist at NYU Langone Perlmutter Cancer Center in New York City, about the use of PARP inhibitors for breast cancer.
Cancer Network spoke with Hank Schmidt, MD, about the 10-year follow-up results of the EORTC AMAROS trial of radiotherapy vs surgery of the axilla in breast cancer patients with a positive sentinel node.
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF's stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer.